Amity Island
Well-Known Member
- Relationship to Diabetes
- Type 1
The Oxford-AstraZeneca Covid-19 vaccine has been branded “defective” in a multi-million pound landmark legal action that will suggest claims over its efficacy were “vastly overstated"
The test cases could pave the way for as many as 80 damages claims worth an estimated £80 million over a condition known as Vaccine-induced Immune Thrombocytopenia and Thrombosis (VITT) that was identified by specialists in the wake of the AstraZeneca Covid-19 vaccine rollout.
In the months following the rollout, the potential serious side effect of the AstraZeneca jab was identified by scientists. Following this, it was recommend it no longer be given to the under-40s in the UK because the risk of receiving the jab outweighed the harm posed by Covid.
The test cases could pave the way for as many as 80 damages claims worth an estimated £80 million over a condition known as Vaccine-induced Immune Thrombocytopenia and Thrombosis (VITT) that was identified by specialists in the wake of the AstraZeneca Covid-19 vaccine rollout.
In the months following the rollout, the potential serious side effect of the AstraZeneca jab was identified by scientists. Following this, it was recommend it no longer be given to the under-40s in the UK because the risk of receiving the jab outweighed the harm posed by Covid.
Oxford AstraZeneca Covid jab was ‘defective’, claims landmark legal case
Victims of VITT - a new condition identified by specialists - question the Government's monitoring of the vaccine's rollout and its efficacy
www.telegraph.co.uk